Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects

NCT05967299 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT05967299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05967299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Phase 1
Overall status
Recruiting
Start date
November 27, 2023
Completion date
November 30, 2027
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension pah